MedTrace Logo

A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

NCT04888949 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-11-18

No results posted yet for this study

Summary

Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.

Conditions

  • SARS-CoV-2 Infection( COVID-19 )

Interventions

BIOLOGICAL

Mesenchymal stem cell

1\*10\^8 cells are administered once a week, total four times intravenously.

BIOLOGICAL

Placebo

Commercially available saline.

Sponsors & Collaborators

  • Rohto Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Okawa Sumito · Rohto Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2023-05-18
Completion
2023-05-18

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04888949 on ClinicalTrials.gov